Back to news

Axogen jumps as investors continue to digest stronger outlook and new prostate program opportunity

Investivoq PriceTracker

Axogen (AXGN) is up 15.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The rally appears tied to a mix of follow-through buying after Axogen’s late-October earnings beat and raised 2026 outlook, plus fresh investor attention after management highlighted a new prostate nerve reconstruction opportunity this week. There does not appear to be a separate major same-day press release, so part of today’s move could be momentum tied to those recent updates.

Details:

  • Axogen reported third-quarter revenue of $75.8 million, up 26.2% year over year, with adjusted net income of $0.21 per share and higher adjusted EBITDA.
  • Management raised full-year 2026 revenue guidance to at least $290 million, implying at least 29% growth, while keeping expectations for positive free cash flow.
  • On November 9, the company posted a prostate program investor presentation that outlined a planned 2027 market development launch and described a potential addressable market of about $754 million.
  • The presentation also highlighted early clinical experience in more than 220 reconstructed patients and the recently completed BioCircuit acquisition, which added the NerveTape product to Axogen’s portfolio.

    • Sources:

    Axogen Investor Relations, SEC, StockAnalysis

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $AXGN Insider Trading Activity

    AXGN Insider Trades

    $AXGN insiders have traded $AXGN stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.

    Here’s a breakdown of recent trading of $AXGN stock by insiders over the last 6 months:

    • MARC A BEGAN (EVP & General Counsel) sold 67,500 shares for an estimated $3,195,787
    • AMY MCBRIDE WENDELL sold 13,353 shares for an estimated $646,592
    • KATHY JOHNSON WEILER sold 14,150 shares for an estimated $640,966
    • JOSEPH A. TYNDALL sold 3,500 shares for an estimated $173,939

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    Investivoq Alerts
    Receive AXGN Data Alerts
    Get market-moving data, filings, and signals for AXGN in real time.
    Sign Up

    $AXGN Hedge Fund Activity

    We have seen 139 institutional investors add shares of $AXGN stock to their portfolio, and 106 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • FMR LLC added 1,415,461 shares (+115.7%) to their portfolio in Q3 2026, for an estimated $59,336,125
    • FIRST LIGHT ASSET MANAGEMENT, LLC removed 1,254,407 shares (-31.3%) from their portfolio in Q2 2026, for an estimated $57,941,059
    • ARROWMARK COLORADO HOLDINGS LLC removed 1,203,644 shares (-62.8%) from their portfolio in Q2 2026, for an estimated $55,596,316
    • HOOD RIVER CAPITAL MANAGEMENT LLC added 1,067,072 shares (+inf%) to their portfolio in Q2 2026, for an estimated $49,288,055
    • RTW INVESTMENTS, LP added 1,011,576 shares (+inf%) to their portfolio in Q2 2026, for an estimated $46,724,695
    • PRICE T ROWE ASSOCIATES INC /MD/ added 967,257 shares (+1904.6%) to their portfolio in Q2 2026, for an estimated $44,677,600
    • DIVISADERO STREET CAPITAL MANAGEMENT, LP removed 925,465 shares (-84.4%) from their portfolio in Q2 2026, for an estimated $42,747,228

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.